The Dystonia drugs in development market research report provides comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dystonia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dystonia and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Dystonia by 12 companies/universities/institutes. The top development phase for Dystonia is preclinical with three drugs in that stage. The Dystonia pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Dystonia pipeline products market are: Neurocrine Biosciences, Teva Pharmaceutical Industries and Tempero Bio.
The key targets in the Dystonia pipeline products market include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25), Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5), and Muscarinic Acetylcholine Receptor M1 (CHRM1).
The key mechanisms of action in the Dystonia pipeline product include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor with six drugs in Pre-Registration. The Dystonia pipeline products include six routes of administration with the top ROA being Intramuscular and three key molecule types in the Dystonia pipeline products market including Small Molecule, and Protein.
Dystonia overview
Dystonia is a neurological hyperkinetic movement disorder in which sustained or repetitive muscle contractions result in twisting and repetitive movements or abnormal fixed postures. Dystonia is often intensified or exacerbated by physical activity, and symptoms may progress into adjacent muscles
For a complete picture of Dystonia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
